Funding for this research was provided by:
Received: 10 October 2022
Accepted: 18 June 2023
First Online: 10 July 2023
: This study was approved by a central institutional review board in the USA (Ethical & Independent Institutional Review Board [Study 19056-01]). Approval of this study was not required by the UK NHS Research Ethics Committee or by local ethics committees in the UK; as determined by the UK’s Health Research Authority decision tool, this study was not defined as research by the UK Policy Framework for Health and Social Care Research primarily because patients were not recruited via the NHS. The study was conducted according to the Code of Conduct for recruiting and interviewing healthcare respondents as published and supported by the professional bodies of the European Society for Opinion and Marketing Research and the European Pharmaceutical Market Research Association. The project was managed according to the European Union General Data Protection Regulation. All study participants provided written informed consent.
: Not applicable.
: MdlOA and CH are employees of Bayer AG. HK and AS are employees of Evidera, which was contracted by Bayer AG to conduct the study. AH was an employee of Evidera at the time of the study and is now an employee of UCB.